12:00 AM
May 20, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Pixuvri pixantrone regulatory update

Germany's Federal Joint Committee (G-BA) issued a final benefit assessment saying cancer drug Pixuvri pixantrone from Cell Therapeutics provides "no additional benefit" over patient-individualized care, G-BA's requested comparator because the company did not submit...

Read the full 148 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >